×
ADVERTISEMENT

DECEMBER 30, 2024

FDA Approves Opdivo Qvantig for Subcutaneous Injection


Originally published by our sister publication Clinical Oncology News

The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo, Bristol Myers Squibb) indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy, Bristol Myers Squibb) combination therapy, or in combination with chemotherapy or cabozantinib.

The approval includes